July 25, 2022
This message includes updates on the COVID-19 response from CDC. The COVID-19 Outbreak is a rapidly evolving situation and information will be updated as it becomes available.
Novavax COVID-19 Vaccine
CDC has endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation that Novavax’s COVID-19 vaccine be used as another primary series option for adults ages 18 years and older.
Novavax is a protein subunit vaccine. These vaccines package harmless proteins of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future.
Vaccines using protein subunits have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough.
Two doses of Novavax are given in the primary series, 3–8 weeks apart. People who are moderately or severely immunocompromised should also receive 2 doses, given 3 weeks apart (a 3rd primary dose is not currently authorized).
Novavax COVID-19 vaccine is not authorized for use as a booster dose.
V-safe After Vaccination Health Checker
Use your smartphone to tell CDC how you, or your dependent, feel after getting any dose of the COVID-19 vaccine. Your participation in V-safe helps CDC monitor the safety of COVID-19 vaccines for everyone.
V-safe provides personalized and confidential health check-ins via text messages and web surveys so you can quickly and easily share with CDC how you, or your dependent, feel after getting a COVID-19 vaccine.
COVID Data Tracker Weekly Review
Staying up to date on COVID-19 vaccines, including boosters, offers the best protection against severe COVID-19. However, millions of people in the U.S. eligible for boosters have not gotten theirs.